Fluid and Imaging Biomarkers and Endpoints in Neuroscience Summit on October 22-24, 2024 in Boston, United States

Accelerating More Sensitive, Quantitative and Predictive Serological and Imaging Biomarkers to Transform Clinical Development in the CNS.

With the Donanemab ADCOM hailing fluid biomarkers as a deciding factor in the unanimous decision, improved plasma ptau 217 markers and PET tracers, and α-syn self-seeding assay sensitivity and enhancing NFL utility beyond SOD-1 ALS, 2024 has opened the floodgates for biomarker innovation.

The 2nd Fluid and Imaging Biomarkers and Endpoints in Neuroscience forum unites biomarker discovery scientists, imaging experts, neuroscience clinical program leads, and regulatory leaders to engage in forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics.

This October, join 90+ biomarker discovery scientists, imaging experts, neuroscience clinical program leaders, and regulatory leaders from renowned organizations like AbbVie, Alector, Biogen, Bristol Myers Squibb, Eli Lilly, Eisai, Pfizer, Takeda, Regeneron, and the Michael J. Fox Foundation and many more at the ultimate unique industry-focused networking opportunity to advance precision medicine in neurodegenerative and neuroinflammatory diseases.

URLs:

Tickets: https://go.evvnt.com/2542184-2?pid=10008

Brochure: https://go.evvnt.com/2542184-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Industry Pricing - Conference and Workshop Day: USD 3597.00,

Industry Pricing - Conference Only: USD 2599.00,

Service and Solution Provider Pricing - Conference and Workshop Day: USD 5197.00,

Service and Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Aarti Narang, Biomarker Clinical Assay Lead, Pfizer, Bradford Navia, Chief Medical Officer, Aprinoia Therapeutics Inc., Bruno Benitez, Professor, Neurology and Neuroscience, Harvard Medical School BIDMC, Carol Singh, Associate Director - Data and Biobank Partnership and Digital Health Lead, Biogen, Chahin Pachai, Director, Medical Imaging, Bristol Myers Squibb, Cristian Salinas, Neuroscience Imaging Lead, Takeda, Elpida Tsika, Senior Team Leader, AC Immune, Enchi Liu, Senior Vice President - Translational Sciences, Tranquis Therapeutics Inc., Erin Rosenbaugh, Project Manager, FNIH, Jamie Eberling, Senior Vice President, The Michael J. Fox Foundation, Jonathan Dubois, Principal Scientist, Biogen, Katia Karalis, Executive Director Research and Development, Regeneron Pharmaceuticals Inc, Maria Laura Blefari, Principal Scientist and Associate Director - Precision Medicine Neuroscience Research, Abbvie, Marla Weetall, Senior Vice President - Pharmacology and Biomarkers, PTC Therapeutics, Omar Mabrouk, Associate Director - Scientific, Biogen, Pallavi Sachdev, Executive Director Translational Science, Clinical Evidence Generation, Deep Human Biology (CEG DHBL), Eisai, Rema Raman, Director of Biostatistics and Recruitment, Engagement and Retention, University of Southern California, Rouba Kozak, Global Biomarker Diagnostic lead, Neuroscience, Novartis AG, Ruchi Gupta, Vice President, Alector Pharmaceuticals LLC, Wesley Horton, Program Manager, FNIH, Ying Wu, Director and Head Of Human Genetics, Eisai